|Novel Cancer Therapeutics Summit|
Oncology Partnering & Deal-Making
Cancer Diagnostics have become fully ingrained in modern cancer treatment programs, and will continue to have an expanding role. Liquid biopsy approaches could exceed imaging in both sensitivity and specificity and yield more information on the tumor. The need for diagnostics for guiding immunotherapy is clear. Precision drug treatment and personal vaccines require a high resolution diagnostic of each tumor.
Technological advances have provided new levels of sensitivity that allow biomarker evaluation in the circulation, expanding the diversity of biomarker targets and facilitating time-based monitoring. In addition, information from the growing array of approaches has identified relevant molecules for targeted drug design. Together, these have facilitated a more intelligent approach to the development of therapy and its delivery to the cancer patient.
We invite you to attend the Cancer Diagnostics Conference, which will take place October 19-20, 2017 in San Diego, CA. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and discuss new research in cancer diagnostics, including next generation sequencing, the use of clinical utility of cell-free DNA liquid biopsy, patient selection for cancer drug development, and correlative predictive markers.
We hope to see you there!
The 2017 Advisory Committee
Amber Kempf at 626-256-6405 x110 or amber.kempf [at] gtcbio.com
For more information on Media Relations, please contact:
Jennifer Chu at 626-256-6405 x105 or jennifer.chu [at] gtcbio.com